Costamare Inc. $0.0001 par value News
Jump on Harley Davidson, but Stay Away From Costamare: 'Mad Money' Lightning Round
Jim Cramer likes Harley and Enterprise Products Partners, but says stay away from Costamare and Achaogen.
Earnings, Not Just the Trump Rally, Drive Stocks: Cramer's 'Mad Money' Recap (Wednesday 1/18/17)
Jim Cramer explains how bullish comments from one semiconductor equipment maker lifts shares throughout the sector.
'Mad Money' Lightning Round: Cramer's bullish on Buffett
Jim Cramer likes Berkshire Hathaway, but cautions investors to stay away from Extra Space Storage and HCP.
Jim Cramer's 'Mad Money' Recap: Willing Buyers Produce Improbable Rally
Short sellers realized their bet was backfiring, says Jim Cramer.
Costamare (CMRE): Today's Weak On High Volume Stock
Trade-Ideas LLC identified Costamare (CMRE) as a weak on high relative volume candidate
3 Hold-Rated Dividend Stocks: ATAX, ARLP, CMRE
These 3 dividend stocks are rated a Hold by TheStreet
What To Hold: 3 Hold-Rated Dividend Stocks TGH, CMRE, AINV
These 3 dividend stocks are rated a Hold by TheStreet
Strong On High Relative Volume: Costamare (CMRE)
Trade-Ideas LLC identified Costamare (CMRE) as a strong on high relative volume candidate
Trade-Ideas: Costamare (CMRE) Is Today's Weak On High Relative Volume Stock
Trade-Ideas LLC identified Costamare (CMRE) as a weak on high relative volume candidate
What To Hold: 3 Hold-Rated Dividend Stocks TAL, ARLP, CMRE
These 3 dividend stocks are rated a Hold by TheStreet
Breaking News
Johnson & Johnson Stock Lower After Unveiling End To Global Baby Powder Sales In 2023
Johnson & Johnson, which began selling Baby Powder in 1894, will end all sales of the talc-based product next year.
Apple Stock Edges Higher After Report Indicates iPhone Demand Confidence
Apple is asking assemblers to put together 220 million iPhones this year, Bloomberg reported, a tally that largely matches 2021 levels.
Rivian Stock Higher As 2022 Production Hopes Offset $5.45 Billion Loss Forecast
"The supply chain continues to be the limiting factor in our production rates but we remain confident in our ability to achieve our target," said CFO Claire McDonough.
Illumina and the Quest for the (Holy?) Grail
DNA-sequencing leader Illumina swung to a loss in Q2 2022. Contributions from Grail didn't help.